ARCT · Company research

Arcturus Therapeutics Holdings Inc. Common Stock (ARCT): Stock News & Events

Recent company-linked news records available in the database.

RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

16records availableHealthcare

Stock News & Events data

Database-backed records only

16 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
ARCT Mar 2027 15.000 put (ARCT270319P00015000) Interactive Stock Chart - Yahoo! Finance CanadaARCT Mar 2027 15.000 put (ARCT270319P00015000) Interactive Stock Chart Yahoo! Finance CanadaView source ↗Yahoo! Finance CanadaOct 15, 2026neutral00.6
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - StocktwitsARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ StocktwitsView source ↗StocktwitsOct 14, 2026neutral00.6
ARCT Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocusARCT Maintained by Leerink Partners -- Price Target Raised to $1 GuruFocusView source ↗GuruFocusOct 9, 2026neutral00.6
Arcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT - MarketBeatArcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT MarketBeatView source ↗MarketBeatOct 8, 2026neutral00.6
A trust joins the reporting parties for 1.68M Arcturus Therapeutics (ARCT) shares. - Stock TitanA trust joins the reporting parties for 1.68M Arcturus Therapeutics (ARCT) shares. Stock TitanView source ↗Stock TitanOct 7, 2026neutral00.6
Discipline and Rules-Based Execution in ARCT Response - Stock Traders DailyDiscipline and Rules-Based Execution in ARCT Response Stock Traders DailyView source ↗Stock Traders DailyOct 6, 2026neutral00.6
Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ) - Seeking AlphaArcturus stock upgraded to Buy at Citi (ARCT:NASDAQ) Seeking AlphaView source ↗Seeking AlphaSep 24, 2026neutral00.6
Why is Arcturus Therapeutics stock surging today? - Investing.comWhy is Arcturus Therapeutics stock surging today? Investing.comView source ↗Investing.comSep 1, 2026neutral00.6
Arcturus will take part in five investor events this September - Stock TitanArcturus will take part in five investor events this September Stock TitanView source ↗Stock TitanAug 31, 2026neutral00.6
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo FinanceArcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? Yahoo FinanceView source ↗Yahoo FinanceAug 27, 2026neutral00.6
Market Movers | Winners: AIAI, ARCT, TMC | Losers: ZIP, NUAI, SA - TrefisMarket Movers | Winners: AIAI, ARCT, TMC | Losers: ZIP, NUAI, SA TrefisView source ↗TrefisAug 24, 2026neutral00.6
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - TradingViewARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ TradingViewView source ↗TradingViewAug 22, 2026neutral00.6
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTradeARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows StocksToTradeView source ↗StocksToTradeAug 19, 2026neutral00.6
ARCT Stock Jumps As Canaccord Backs Vaccine Reset - Timothy SykesARCT Stock Jumps As Canaccord Backs Vaccine Reset Timothy SykesView source ↗Timothy SykesAug 19, 2026neutral00.6
Arcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk - Simply Wall StreetArcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk Simply Wall StreetView source ↗Simply Wall StreetAug 8, 2026neutral00.6
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? - Yahoo FinanceArcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? Yahoo FinanceView source ↗Yahoo FinanceJul 3, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.